⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL6056947 | 1.00 | — | — | |
| Dimethylamine SCHEMBL27929426 | 1.00 | KDM4E (0.38) | — | |
| Dimethylamine SCHEMBL6288928 | 0.91 | — | — | |
| Dimethylamine SCHEMBL28552843 | 0.91 | — | — | |
| Dimethylamine SCHEMBL28249086 | 0.91 | — | — | |
| Dimethylamine SCHEMBL21876862 | 0.91 | — | — | |
| Dimethylamine SCHEMBL5164633 | 0.89 | — | — | |
| Dimethylamine SCHEMBL12415750 | 0.89 | — | — | |
| Dimethylamine SCHEMBL1030 | 0.89 | — | — | |
| Dimethylamine SCHEMBL392668 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779138-B2 | Camptothecin derivatives as chemoradiosensitizing agents | Sutter West Bay Hospital (US) | 2014-07-15 | — | — | US | disclosed |
| US-8563537-B2 | Camptothecin derivatives as chemoradiosensitizing agents | Sutter West Bay Hospital (US) | 2013-10-22 | — | — | US | disclosed |
| EP-1951231-B1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MED CENTER (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20110184009-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2011-07-28 | — | — | US | disclosed |
| US-7875602-B2 | Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in cancer treatment in combination with radiotherapy; less toxic | SUTTER WEST BAY HOSPITALS (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080318873-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER | 2008-12-25 | — | — | US | disclosed |
| EP-1951231-A2 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | California Pacific Medical Center (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007048002-A2 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | CALIFORNIA PACIFIC MEDICAL CENTER | 2007-04-26 | — | — | US | disclosed |
| EP-1023308-A4 | INHIBITORS OF NUCLEOSIDE METABOLISM | EINSTEIN COLL MED (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1023308-A1 | INHIBITORS OF NUCLEOSIDE METABOLISM | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999019338-A1 | INHIBITORS OF NUCLEOSIDE METABOLISM | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-04-22 | — | — | WO | disclosed |